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ABSTRACT 
 
CAPILLARY ELECTROPHORESIS USED AN ALTERNATIVE TO HPLC FOR 
PHARMACEUTICAL ANALYSIS OF ANTIFUNGAL AGENTS 
 
HPLC is a commonly used analytical tool in the pharmaceutical industry for the 
characterization of drug potency and purity.   However, HPLC analysis can be very 
time consuming, use large quantities of organics, and thus costly and not 
environmentally friendly.  In this study, we describe an alternative to HPLC that can 
be used for pharmaceutical analysis.  Capillary electrophoresis is being utilized 
increasingly for biochemistry and analytical chemistry applications.  With advances in 
auto samplers and improvements in injection precision, the potential for this 
instrumentation to be used in conjunction or as an alternative to HPLC is currently 
being evaluated in analytical laboratories.  Capillary electrophoresis allows for 
minimal organic consumption, fast analysis time, and high degree of resolution.  In 
addition, capillary electrophoresis assays are more cost effective to develop and run 
on a routine basis due to relatively less expensive capillaries and small amounts of 
organic solvents.  In this study, capillary electrophoresis is used for analysis of 3 
classes of antifungal compounds; an imidazole, polyene and a pyrimidine, 
represented by miconazole, nystatin and 5-fluorocytosine.  Utilizing USP validation 
criteria, we find comparable levels of accuracy, limit of detection (LOD), limit of 
quantification (LOQ), linearity, and precision to HPLC.  Using,  a 40 cm x 75 μm 
capillary with a KH2P04 run buffer for both miconazole and 5-fluorocytosine, we show 
that both agents can be captured in less than 3 minutes with a %RSD < 2.0%, and a 
linearity R2 > 0.99.  For nystatin, there were solution solubility issues due to the 
organic: aqueous ratio and further investigation is needed to determine if  
comparable data to HPLC can be obtained.
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INTRODUCTION 
 
Capillary electrophoresis (CE) was developed in the early 1990s and has become an 
established analytical instrument in many laboratory and clinical settings with the 
exception of pharmaceutical analytical laboratories where HPLC has been the 
analytical tool of choice for the characterization of drug potency and purity.   In most 
cases HPLC analysis is very time consuming and uses large quantities of organics 
and thus has higher associated method development and routine operational costs.    
There are many compounds for which HPLC is the optimal analytical instrument.  
However, there are compounds that potentially can be assayed with capillary 
electrophoresis and the CE’s advantages of fast analysis times, smaller quantities of 
solutions and minimal organic usage, and thus overall lower consumable expenses 
can be attained.   The typical amount of buffer utilized per day can be in the order of 
10-100 milliliters, in comparison to HPLC which can consume liters of organic. In 
addition to fast analysis and cost savings, due to the inherent advantage of minimal 
band broadening/peak spreading, capillary electrophoresis can produce very defined 
peaks with a high degree of resolution [2].   A potential drawback to HPLC is the 
limitation of pH range to the bonded-phase materials in the columns.  In comparison, 
CE separation is achievable in a wide pH range [7].   Injection precision has been 
one area that CE has been in need of improvement.  The volume injected is strongly 
related to the viscosity of the sample [4].  Thus, internal standards have been 
commonly used for analysis.  
Electrophoresis has been defined as the differential movement of charged species 
(ions) by attraction or repulsion in an electric field [1]. Automated capillary 
electrophoresis separates species by applying voltage across buffer filled capillaries.  
It has been used more commonly for the separation of ions, which depending on size 
and charge, move at various speeds when voltage is applied.  These solutes are seen 
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as peaks as they pass through a detector.   Electrophoresis can be defined as the 
migration of ions under the influence of an electric field, FE, which is proportional to 
its effective charge, q, and the electric field strength, E.  (FE = qE) [8]. 
The main separation modes used in capillary electrophoresis include capillary zone 
electrophoresis, micellar electrokinetic capillary chromatography, capillary 
isotachophoresis, capillary gel electrophoresis, and capillary isoelectric focusing.  For 
the purpose of this study, capillary zone electrophoresis (CZE) will be employed.  In 
this mode, the sample is applied as a narrow zone (band), which is surrounded by 
the separation buffer.  As the electric field is applied, each component in the sample 
zone migrates according to its own apparent mobility.  It is intended that all sample 
components will eventually separate from each other to form individual zones of pure 
material.  In practice, neutral molecules cannot be separated due to the fact that 
they migrate at the velocity of the electroosmotic flow.  The separation of charged 
molecules is accomplished most effectively when the differences among the 
velocities of the solutes are maximized and random dispersion of the zones are 
minimized.   Cations migrate through the capillary in the same direction as 
electroosomitic flow, from the anode to the cathode.  Cations also migrate at a faster 
rate than the electroosomitc flow.  They elute in order of their charge-to-size ratios, 
thus the small, highly charged cations elute first.  As noted, neutral molecules are 
not separated from each other, but move through the capillary under the influence of 
only the electroosmotic flow. Anions elute in reverse order to their charge-to-size 
ratios with the small, highly charged anions eluting last.  Thus, the overall elution 
order will be small highly charged cations, neutral molecules, and small highly 
charged anions eluting last [8]. 
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For the purpose of this investigation three classes of antifungals will be examined 
with capillary electrophoresis.  An imidazole, a polyene, and a pyrimidine, 
represented by miconazole, nystatin, and 5-fluorocytosine respectively.  
               
Miconazole                       Nystatin                               5-fluorocytosine 
The molecular weight for these compounds are 416.12, 926.11, and 129.09 for 
miconazole, nystatin, and 5-fluorocytosine respectively.    The USP criteria that will 
be evaluated in this study are linearity, precision, quantitation limit (LOQ), and 
detection limit (LOD).  The linearity of an analytical procedure is the ability to yield 
test results that are directly proportional to the concentration of the analyte in the 
samples within a given range [3].  Precision refers to the degree of agreement 
among injections of the same solution [3]. The quantitation limit refers to the lowest 
amount of analyte that can be quantified.  The detection limit is the lowest amount 
of analyte that can be detected, but not necessarily quantified [3].   
 
Other similar studies have shown capillary electrophoresis as being comparable to 
HPLC.  In one such study, CE was utilized in a pharmaceutical quality control 
laboratory.  Typical drug CE assays were found to have 1% RSD, with linearity 
values of R2=0.999.  Other factors, such as method robustness, sensitivity, accuracy, 
and reagent stability were comparable to HPLC [4]. 
In a similar study, CE was used for the quantification of mirtazapine and related 
impurities. The %RSD standard values were found to be between 2-3%, which 
required the use of an internal standard.  However, other validated method criteria 
were found to be comparable to HPLC [6]. 
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 In yet another study, a validated method utilizing single borate buffer allowed for 
analysis of a wide range of acidic compounds, including active drugs, excipients, 
starting materials, and intermediates.  The method allowed for acceptable injection 
precision with use of an internal standard.  The cost and time savings in comparison 
to HPLC were found to be significant [5]. 
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MATERIAL AND METHODS (EXPERIMENTAL DESIGN) 
 
Three separate methods were developed, and subsequent experiments were 
performed on a Beckman Coulter Capillary electrophoresis system with a Photo-
diode-array (PDA) detector.  The system was run with Beckman Coulter 32 Karat 
v8.0 software. Data was collected with Waters Empower data collection system.  A 
fused-silica capillary at 40cm in length to the detector window and an internal 
diameter of 75µm was used for all tests.   
 
The hydrodynamic injection volume for 5-fluorocytosine was 43nL, which 
corresponds to a sample introduction at 0.4psi for 9 seconds.  The hydrodynamic 
injection volume for miconazole was 115nL, which corresponds to a sample 
introduction at 0.8psi for 12 seconds. The hydrodynamic injection volume for 
nystatin was 14nL, which corresponds to a sample introduction at 0.3psi for 4.0 
seconds. For detection, the PDA detector was at 214nm for all three compounds.  
Voltage used for analysis were 25kV, 20kV, and 30kV for 5-fluorocytosine, 
miconazole, and nystatin respectively.  The capillary temperature was set to 25°C.  A 
10 mM potassium phosphate (monobasic) buffer (KH2PO4), pH7.0 was used for both 
5-fluorcystosine and Nystatin.  A 50mM KH2P04 was utilized for miconazole.  Data 
analysis time was 4 minutes for 5-fluorocytosine, 7 minutes for miconazole, and 3 
minutes for nystatin.   
 
Table 1. Antifungal CE Method Instrument Parameters 
Antifungal 
Agents 
Analysis 
Time 
Buffer Injection 
Volume 
(nL) 
Temperature 
(°C) 
Voltage 
(kV) 
5-fluorocytosine 4 minutes 10mM KH2PO4, pH 
7.0 
43 25.0 25 
Miconazole 7 minutes 50mM KH2PO4, pH 
4.5 
115 25.0 20* 
Nystatin 3 minutes 10mM KH2PO4, pH 
7.0 
14 25.0 30 
* (reverse polarity applied)  
Table 2. REAGENTS 
Reagent 
Potassium phosphate monobasic (KH2PO4) 
50% Sodium Hydroxide 
Methanol 
Millipore Water 
Dimethylformamide 
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 BUFFER SOLUTIONS 
 
Potassium phosphate monobasic (KH2PO4) at working concentrations of 10mM and 
50mM were weighed out on a Mettler-Toledo analytical balance.  For miconazole, 
3.45g of KH2PO4 was transferred to 500 ml of Millipore water.  For 5-fluorocytosine 
and nystatin 1.36g of KH2PO4 was transferred to 1 liter of Millipore water.  The pH 
was adjusted for the 10mM concentration to 7.0 using 50% sodium hydroxide.  All 
solutions were vacuum/degassed for about 10 minutes and filtered through a 0.2µm 
(PALL) nylon membrane filter before loading into the autosampler. 
 
REFERENCE SOLUTIONS 
 
 
Table 3. Reference Standards  
Standard 
5-fluorocytosine 
Miconazole 
Nystatin 
 
 
Reference stock solutions were prepared at initial concentrations of 2.0mg/ml for all 
3 antifungal agents.  Miconazole was dissolved in 100% methanol.  5-fluorocytosine 
was dissolved into the 10mM KH2PO4, pH7.0 buffer.  Nystatin was dissolved into a 
50:50 solution of dimethylformamide and KH2PO4, pH7.0 buffer.   
For the linearity study, a concentration range of 0.7mg/ml to 1.3 mg/ml was 
prepared for both miconzole and 5-fluorocytosine.  A reference point (100%) at 
1.0mg/ml was established, and thus the overall range represented 70% to 130%.  
 
Due to the higher molecular weight of nystatin, a lower target reference 
concentration of 0.5mg/ml was selected as the reference 100%.  The linearity 
solutions ranged from 0.00025mg/ml to 1.1 mg/ml.  For nystatin, the 0.00025mg/ml 
solution represented the Limit of Quantification (LOQ) concentration, which is 0.05% 
of the target concentration of 0.5mg/ml.  The overall linearity range evaluated was 
0.05% to 220% of target of 0.5mg/ml. 
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An additional check solution was prepared for each compound at the target 
concentration of 0.5mg/ml for nystatin and 1.0mg/ml for 5-fluorocytosine and 
miconazole. 
 
All above outlined working standard solutions were dissolved into their respective   
buffers.  For miconazole solutions, 50mM KH2P04, pH 4.5 buffer and for 5-
fluorocytosine and nystatin, 10mM kH2P04, pH 7.0 buffer.  All solutions were filtered 
through a 0.2µm nylon membrane filter before loading into the autosampler. 
 
A limit of detection (LOD) and limit of quantification (LOQ) study was prepared for 5-
fluorocytosine since this was the smallest molecule of the group and thus was used 
to challenge the CE system.  A concentration of 0.0005mg/ml, representing 0.05% 
of the 1mg/ml target concentration was prepared. 
 
COLUMN REGERNATION/WASH SOLUTION 
After every 5 or 7 seven-sample injections, the capillary was washed with 0.1M 
sodium hydroxide at 20psi for 1 minute.   
 
RESULTS AND DISCUSSION 
 
 
Influence of Buffer Concentration and Voltage 
 
In capillary electrophoresis, in addition to solutes, the run buffer also moves through 
the capillary under the influence of an electric field [8].  This phenomenon is referred 
to as electroosmotic flow [8]. 
The ionic strength of KH2P04 was examined to determine effect of peak elution and 
peak symmetry.  If temperature is controlled, an increase in the buffer ionic strength 
will reduce the electroosmotic flow.  However, if temperature is not controlled, an 
increase in buffer ionic strength will increase the osmotic flow due to and increase in 
current and temperature which will lower viscosity [9].  In general although lower 
buffer concentrations should produce faster analysis times; concentrations that are 
excessively low may produce broadened and asymmetric peak shapes [9].   For this 
study, the capillary temperature was set to a 25C.     Considering only one analyte 
was needed to be separated per analysis, the findings with regard to voltage and 
buffer concentration effected elution time and peak shape mainly.  With one analyte 
13  
involved there was considerable flexibility in choosing a final buffer/voltage 
combination. 
 
 
For all conditions, the capillary temperature was set to 25°C.  Miconazole was 
examined with both 50mM pH 4.5, and 100mM, pH 4.5 kH2P04 run buffer.  There 
was a slight increase in retention time for Miconazole with the 100mM run buffer if 
the voltage was the same.  The differences between the buffer concentrations were 
less than 1 minute.    With a higher ionic strength run buffer, higher current levels 
were generated with the same voltage.  Although, initially there did not seem to be 
any negative influence, a concern with joule heating was considered when higher 
currents were generated.  With the longer analysis times needed for the linearity 
study, this was a reason for concern.  Thus, a balance of the run buffer ionic strength 
and voltage was needed to provide quick elution time, without generating too much 
system current and thus heating.  A 50mM KH2P04, pH 4.5 with 20KV was decided 
upon for the miconazole assay.  The 50mM KH2P04 provided for a peak elution time 
of miconazole at about 3 minutes and less current generation. 
 
As discussed, different voltages ranging from 10kV to 30kV were also examined in 
conjunction with buffer concentrations. Considering the electric field, E, is the 
voltage/length, changing the voltage allows for a modification of the electoosmotic 
flow due to the variation in the electric field [8].  An increase in voltage will increase 
the electroosmotic flow and reduce analyte retention times.  The utilization of higher 
voltages will provide higher efficiencies.  However, high voltages will also produce 
increased joule heating due to the production of higher current. 
With regard to 5-fluorocytosine and nystatin, it was decided to evaluate a 10mM 
KH2P04 run buffer.  The benefit of this concentration allowed for more flexibility in 
terms of selecting voltages.  The lower buffer concentration produced less current 
and therefore less heat with a given voltage setting. 
 
For 5-fluorocytosine, a 10mM KH2P04 run buffer with 25kV of voltage was utilized.  A 
voltage setting of 30kV was used with the 10mM KH2P04 run buffer for nystatin.    
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Influence of pH 
 
The run buffer pH has a significant effect on electroosomotic flow because it changes 
the zeta potential, which is proportional to the surface charge on the capillary wall.  
As the pH of the run buffer increases, there is an increase in the electroosmotic flow, 
due to the fact that there is more dissociation of the Si-OH to Si-O- on the inner 
capillary wall.  In addition, at higher pH there are more charged Si-O- groups and, 
thus a greater zeta potential leading to an increase in electroosmotic velocity.  
Conversely, at lower pH levels there is less surface ionization and a lower zeta 
potential [8].  The run buffer pH will also have impact on the degree of ionization of 
the solutes and thus their mobility’s [8]. 
 
pH can potentially play a greater role than buffer concentration and voltage in the 
final result of an assay.  For this investigation, with only one analyte to evaluate, 
differences in buffer pH did not significantly influence the chromatography.  Thus, 
there was more flexibility in determining a suitable pH.  For an analysis with multiple 
analytes to separate, the pH of the buffer would play a large role.  It is likely that 
slight changes would influence the separation characteristics significantly.  
In general it is recommended to select a run buffer at pH around or slightly lower 
than the pKa value of the compound.  Miconazole and 5-fluorocytosine have pKa 
values of 6.7 and 3.2 respectively.  However, initially run buffers of pH 3.0 and 4.5 
were prepared at both the 50mM and 100mM concentrations for miconazole.  At 
each buffer concentration, pH 4.5 yielded a slightly quicker elution time.  
For 5-fluorocytosine, 10mM KH2P04 buffer was prepared at pH 11.0 and 7.0 It was 
found that the peak shape was more symmetrical with the buffer at pH 7.0.  In 
addition analyte elution time was quicker.  The finding with nystatin was similar; with 
peak shape significantly better at pH 7.0 than at pH 11.0. 
Additional investigations with regard to pH possibly would have yielded even better 
chromatography (in terms of peak shape), particularly with miconazole.  However, 
the validation criteria of this study were sufficiently met with the selected buffer pH. 
  
Influence of Temperature 
An increase in temperature can cause an increase in electroosmotic flow due to a 
decrease in the viscosity of the buffer [8].  A 1°C temperature increase will cause a 
2.4% decrease in the viscosity of water [8].  An increase in temperature also will 
cause a decrease in the dielectric constant, which will decrease the electroosmotic 
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flow [8].  Thus, it would seem that these two factors would cancel each other.  
However, the decrease in dielectric constant for water is minimal. Thus, the change 
in viscosity would have the greatest effect on electroosmotic flow [8].  As noted in 
the buffer molarity and voltage discussion, maintaining a set temperature is essential 
to avoid thermal heating.   For this study, the temperature was set to 25°C.  No 
additional experiments were performed to evaluate the effect of temperature 
changes. 
 
Influence of organic solvent 
 
Due to the solubility properties of miconazole and nystatin, organic solvents were 
needed.  Miconazole is soluble in methanol, and nystatin is soluble in 
dimethyformamide.  Miconazole was dissolved in 100% methanol for the stock 
(initial) standard solution.  For nystatin, the stock standard solution was dissolved in 
a 50:50 dimethylformamide and 10mM KH2P04, pH 7.0 buffer.  This ratio of (50:50 
aqueous:organic) caused solution solubility issues that were apparent when 
reviewing the results of the linearity study as discussed later in the findings. In 
addition, although the precision study yielded replicate injections of less than 2.0%, 
it is believed that the solution stability of nystatin also adversely affected precision. 
The effect of organic solvent can be variable due to several factors including 
viscosity, dielectric constant, and zeta potential [8].   However, for the purpose of 
meeting the validation criteria of linearity and precision considered in this study, it 
was necessary to minimize as much a reasonable the amount of organic added to the 
final antifungal working standards.  
This was not an issue for 5-fluorocytosine due to its solubility in water.  For 
miconaolze and nystatin, a balance was needed to be achieved between the levels of 
organic and water.  If the organic level was too high in the final working standard 
solutions, precision would be adversely affected.  In addition, current generation 
could be inhibited if the organic level was too high in the sample. 
Initially miconazole was prepared for analysis in a (25:75 water:methanol) solution.  
Relative standard deviation (%RSD) was typically found at around 5% - 7%.  New 
solutions were prepared at a ratio of (50:50 methanol and 50mM KH2P04, pH 4.5) 
run buffer.  This resulted in better sample precision with values of less than 2.0% 
RSD for all concentration levels. 
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The findings were similar for nystatin and the use of dimethlyformamide to dissolve 
the compound.  The final working solutions for nystatin were at (25:75 organic to 
KH2PO4, pH 7.0) run buffer.  Although injection precision was less than 2% RSD; 
higher values were found in comparison to miconazole and 5-fluorocytosine (see 
table).  However, the results of linearity study with R2 values at 0.89 were not 
acceptable.  It was first considered that the issue was due to not allowing enough 
time for cooling the mixture of dimethylformamide and buffer, when preparing the 
final working solutions.  In a second preparation of the working standard solutions, a 
considerably longer amount of time was allowed for more than adequate solution 
cooling.  The results of this analysis (data not shown) were the same as the first 
analysis.  Upon visual inspection of the flasks, there did not appear to be any 
particulate formation.  However, since precision results were less than 2.0% across 
the entire concentration range, it is believed that the level of buffer in the working 
solutions was too high and nystatin was not stable in the solution.  Further 
investigation was not performed, but this can potentially cause problems with 
molecules that have solubility issues in an partially aqueous environment. 
 
Influence of buffer depletion and vial levels  
 
The influence of run buffer depletion was evaluated during this study.  A number of 
factors are involved before run buffer “depletion” and loss of effectiveness.  Changes 
in buffer pH or composition can cause changes in electroosmotic flow, which will 
result in changes in migration times and peak areas [8].  
 
Another consideration to buffer depletion is change in the composition of the solution 
itself.  Buffer pH in the source and destination vials can change.  This can occur due 
to electrolysis of water, where protons are produced at the cathode and hydroxide 
ions at the anode [8].  In addition, changes in buffer can occur due to the 
electrolysis and migration of buffer ions.  Finally, buffer composition can change in 
the destination vial if solute ions exit the capillary.  If there are sufficient quantities 
of solutes present in the destination vial, a change in the electric field could occur 
which in turn could change the electric field strength in the capillary.   
With regard to nystatin, it could also be possible that nystatin stability changed the 
composition of the destination vial.   
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Overall, the number of injections that can be made between replenishment with new 
buffer is dependent on the magnitude and duration of the current flow, the volumes 
and quantities of the sample injected, and the buffer’s capacity [8].  
 
In this study, there did not appear to be a set consistent number of injections that 
could be performed before adverse affects in chromatography were observed.  
However, for both the 10mM and 50mM KH2PO4 buffers used, it was apparent that at 
least 10 samples could be analyzed before the possibility of adverse effects.  
  
Another factor to be considered is source and destination run buffer vial levels.  It is 
critical the level of these vials be even.  If for example the level of the source vial is 
higher than the destination vial, siphoning will occur and thus introduce laminar flow 
[8].  The result would be shorter peak elution time.  Conversely, if the level of the 
destination vial was higher than the source vial, migration times would be longer.  
Since migration time changes would occur, peak area could also change as a result.  
 
Influence of capillary conditioning and regenerating 
 
During method development for all 3 antifungal agents, the effect of both capillary 
conditioning and regenerating was evaluated.  It was determined early on that an 
injection of the run buffer with voltage would be applied before the  sample injection. 
The electroosmotic flow and migration times are very sensitive to conditions of the 
capillary surface.  Preconditioning the capillary influences migration times [8]. The 
equilibration injection marginally improved the %RSD between multiple injections.  It 
also provided an additional benefit as a column wash to ensure there would be no 
carry-over.  In addition, peak retention times were found to be consistent within 
each analysis. 
 
In addition to an equilibration injection before introduction of the sample, the 
capillary was regenerated after every 5-12 injections with 0.1M sodium hydroxide.  
Washing the capillary with a basic solution regenerates the silica surface by removing 
any solutes or buffer ions from the inner wall [8].  Since the silica is soluble in basic 
solution, some silica is dissolved and new silica is exposed.  Washing a capillary with 
0.1M sodium hydroxide is beneficial if the migration times are initially unstable [8]. 
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During the development of the miconazole and 5-fluorocytosine methods, the 
capillary was regenerated with 0.1M sodium hydroxide after every 10-12 injections.  
With the nystatin analysis, the capillary was regenerated after every 5-7 injections. 
 
Influence of sample introduction and time 
 
Unlike HPLC where injection volume is selected; for capillary electrophoresis sample 
introduction is achieved by pressure and time for hydrodynamic injections used in 
this study.  The Hydrodynamic injection mode was selected since it is believed to be 
more precise and robust than electrokinetic injection [10].  The injection conditions 
are generally only affected if the viscosity of the buffer is drastically changed by 
temperature. Similar to other method development parameters for this instrument, 
there does not seem to be a rule or setting that will produce the best results.  
Instead, it is a matter of optimization for the particular compound and buffer.  
However, longer, lower pressure injection gives the instrumentation more time to 
respond to variances and will potentially provide a better result [11].  After the 
pressure was selected, the longest reasonable injection time was allotted without 
increasing the sample injection volume significantly. In this study, no significant 
findings were apparent from varying injection pressure and time.  Thus, parameters 
were selected based on molecule size.   In the case of miconazole, however, a 
greater injection volume was selected relative to the smaller 5-fluorocytosine, to 
achieve good precision.   
 
Linearity, Precision, LOQ, and LOD Results 
 
The focus of this study has been to achieve results similar to HPLC for linearity and 
precision.  Although the system was challenged with only one analyte, comparable 
findings are shown with miconazole and 5-fluorocytosine.  Refer to the data tables to 
obtain all the results related to these studies. 
Overall for miconazole, standard agreement at 5 injections was found to be less than 
2.0% for all concentration levels.  The results of the linearity study show  R2 values 
at 0.996 (study 1) and R2 values at 0.994 (study 2). 
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The results are similar for 5-fluorocytosine, with precision values of less than 2.0% 
and R2 values at 0.998 for the linearity study.  A limit of quantification (LOQ) result 
of signal to noise ratio of 11, with a 3.4% RSD, was achieved at a concentration  of 
0.0025mg/ml.   A limit of detection (LOD) result with signal to noise ratio of 4, 
26.0% RSD, was found at a concentration of 0.0005mg/ml. 
 
Nystatin proved to be more challenging to work with than miconazole and 5-
fluorocytosine.  With further investigation, the results for this compound may be  
very similar.  With regard to precision, less than 2.0% RSD was achieved throughout 
each concentration level.  As discussed previously, due to solution solubility issues, 
the results of linearity were not acceptable as per USP validation criteria. 
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Analytical Data for Miconazole 
 
Table 4. (Miconazole – check standard analysis MCZ_std_validation_061808) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
Miconazole – 1.0mg/ml 1 3389 2.75 804550 
Miconazole – 1.0mg/ml 2 3390 2.75 810536 
Miconazole – 1.0mg/ml 3 3391 2.76 813068 
Miconazole – 1.0mg/ml 4 3392 2.75 812577 
Miconazole – 1.0mg/ml 5 3393 2.76 817372 
     
Mean    811621 
%RSD    0.6 
 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
Miconazole – 1.0mg/ml (check) 1 3394 2.75 813855 
Miconazole – 1.0mg/ml (check) 2 3395 2.75 821108 
     
Mean    817482 
%RSD    0.6 
 
Average areas used for calculations 
Miconazole standard weight = 500.48mg/250ml volumetric flask 
Miconazole check standard weight = 100.56mg/50ml volumetric flask 
Standard Agreement = 99.7% 
 
Sample Set Name:  CNL_MCZ_Lin_study1_061808  
 
Table 5. (Miconazole Linearity Study)  
Sample Name Injection 
number 
Retention 
Time 
Area 
Miconazole - 0.7 mg/ml 1 2.79 564064 
Miconazole - 0.7 mg/ml 2 2.80 577168 
Miconazole - 0.7 mg/ml 3 2.78 564049 
Miconazole - 0.7 mg/ml 4 2.76 581151 
Miconazole - 0.7 mg/ml 5 2.75 581389 
    
Mean   573564 
% RSD   1.5 
 
Table 6. (Miconazole Linearity Study 1)  
Sample Name Injection 
number 
Retention 
Time 
Area 
Miconazole - 0.8 mg/ml 1 2.73 653576 
Miconazole - 0.8 mg/ml 2 2.72 668840 
Miconazole - 0.8 mg/ml 3 2.73 683716 
Miconazole - 0.8 mg/ml 4 2.73 675764 
Miconazole - 0.8 mg/ml 5 2.73 673544 
    
Mean   671088 
% RSD   1.7 
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Table 7. (Miconazole Linearity study 1)  
Sample Name Injection 
number 
Retention 
Time 
Area 
Miconazole - 1.0 mg/ml 1 2.75 819261 
Miconazole - 1.0 mg/ml 2 2.75 838945 
Miconazole - 1.0 mg/ml 3 2.75 830247 
Miconazole - 1.0 mg/ml 4 2.75 824237 
Miconazole - 1.0 mg/ml 5 2.75 818514 
    
Mean   826241 
%RSD   1.0 
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    Figure 1. (miconazole 1.0mg/ml concentration) 
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Table 8. (Miconazole Linearity Study 2- CNL_MCZ_Lin_study1_062108)  
Sample Name Injection 
number 
Result ID Retention 
Time 
Area 
Miconazole - 0.9 mg/ml 1 4143 2.76 732972 
Miconazole - 0.9 mg/ml 2 4144 2.74 709822 
Miconazole - 0.9 mg/ml 3 4145 2.73 739711 
Miconazole - 0.9 mg/ml 4 4146 2.73 735856 
Miconazole - 0.9 mg/ml 5 4147 2.72 742759 
     
Mean    732224 
% RSD    1.8 
 
Table 9. (Miconazole Linearity Study 2)  
Sample Name Injection 
number 
Result ID Retention 
Time 
Area 
Miconazole - 1.0 mg/ml 1 4148 2.74 841296 
Miconazole - 1.0 mg/ml 2 4149 2.74 854341 
Miconazole - 1.0 mg/ml 3 4150 2.74 855083 
Miconazole - 1.0 mg/ml 4 4151 2.74 845032 
Miconazole - 1.0 mg/ml 5 4152 2.74 848947 
     
Mean    848940 
% RSD    0.7 
 
 
 
 
 
Table 10. (Miconazole Linearity Study 2)  
Sample Name Injection 
number 
Result ID Retention 
Time 
Area 
Miconazole - 1.1 mg/ml 1 4153 2.79 930245 
Miconazole - 1.1 mg/ml 2 4154 2.79 930178 
Miconazole - 1.1 mg/ml 3 4155 2.77 924661 
Miconazole - 1.1 mg/ml 4 4156 2.77 924809 
Miconazole - 1.1 mg/ml 5 4157 2.76 927187 
     
Mean    927416 
%RSD    0.3 
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Table 11. (Miconazole Linearity Study 2)  
Sample Name Injection 
number 
Result ID Retention 
Time 
Area 
Miconazole - 1.2 mg/ml 1 4158 2.78 990378 
Miconazole - 1.2 mg/ml 2 4159 2.77 1006883 
Miconazole - 1.2 mg/ml 3 4160 2.77 1001676 
Miconazole - 1.2 mg/ml 4 4161 2.76 1004755 
Miconazole - 1.2 mg/ml 5 4162 2.77 1014703 
     
Mean    1003679 
%RSD    0.9 
 
Table 12. (Miconazole Linearity study 2)  
Sample Name Injection 
number 
Result ID Retention 
Time 
Area 
Miconazole - 1.3 mg/ml 1 4163 2.83 1074690 
Miconazole - 1.3 mg/ml 2 4164 2.83 1097089 
Miconazole - 1.3 mg/ml 3 4165 2.83 1104802 
Miconazole - 1.3 mg/ml 4 4166 2.82 1100162 
Miconazole - 1.3 mg/ml 5 4167 2.82 1102949 
     
Mean    1095939 
%RSD    1.1 
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Table 13.  (5-fluorocytosine – check standard analysis (5-fluorocytosine_std_check062508) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
5-fluorocytosine – 1.0mg/ml (check) 1 6302 2.28 1214582 
5-fluorocytosine – 1.0mg/ml (check) 2 6303 2.28 1216093 
5-fluorocytosine – 1.0mg/ml (check) 3 6304 2.28 1208542 
5-fluorocytosine – 1.0mg/ml (check) 4 6305 2.28 1212621 
5-fluorocytosine – 1.0mg/ml (check) 5 6306 2.27 1219786 
     
Mean    1214307 
%RSD    0.3 
 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
5-fluorocytosine – 1.0mg/ml  1 6307 2.28 1189910 
5-fluorocytosine – 1.0mg/ml  2 6308 2.28 1186187 
     
Mean    1188263 
%RSD    0.2 
 
 
Note: for this analysis voltage and injection volume different than linearity analysis 
 
(average areas used for calculations) 
5-fluorocytosine standard weight = 500.61mg/250ml volumetric flask 
5-fluorocytosine check standard weight = 100.44mg/50ml volumetric flask 
Standard Agreement = 98.2% 
 
   Figure 6. (5-fluorocytosine 1.0mg/ml – check standard) 
 
32  
 
 
 
Table 14.  (5-fluorocytosine Linearity Study - 5fluorocytosine_linstudy_062608) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
5-fluorocytosine – 0.7mg/ml 1 4648 1.87 725313 
5-fluorocytosine – 0.7mg/ml 2 4649 1.86 721134 
5-fluorocytosine – 0.7mg/ml 3 4650 1.85 712320 
5-fluorocytosine – 0.7mg/ml 4 4651 1.85 709312 
5-fluorocytosine – 0.7mg/ml 5 4652 1.85 707725 
     
Mean    715161 
% RSD    1.1 
 
 
Table 15.  (5-fluorocytosine Linearity Study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
5-fluorocytosine – 0.8mg/ml 1 4653 1.84 780866 
5-fluorocytosine – 0.8mg/ml 2 4654 1.84 780599 
5-fluorocytosine – 0.8mg/ml 3 4655 1.84 790593 
5-fluorocytosine – 0.8mg/ml 4 4656 1.84 789084 
5-fluorocytosine – 0.8mg/ml 5 4657 1.84 787709 
     
Mean    785770 
% RSD    0.6 
 
 
Table 16.  (5-fluorocytosine Linearity Study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
5-fluorocytosine – 0.9mg/ml 1 4658 1.85 878242 
5-fluorocytosine – 0.9mg/ml 2 4659 1.84 874627 
5-fluorocytosine – 0.9mg/ml 3 4660 1.84 873882 
5-fluorocytosine – 0.9mg/ml 4 4661 1.85 891805 
5-fluorocytosine – 0.9mg/ml 5 4662 1.85 884914 
     
Mean    880694 
%RSD    0.9 
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Table 17.  (5-fluorocytosine Linearity Study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
5-fluorocytosine – 1.0mg/ml 1 4663 1.84 951970 
5-fluorocytosine – 1.0mg/ml 2 4664 1.84 952122 
5-fluorocytosine – 1.0mg/ml 3 4665 1.84 961131 
5-fluorocytosine – 1.0mg/ml 4 4666 1.84 957239 
5-fluorocytosine – 1.0mg/ml 5 4667 1.84 957123 
     
Mean    955917 
% RSD    0.4 
 
Table 18.  (5-fluorocytosine Linearity Study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
5-fluorocytosine – 1.1mg/ml 1 4668 1.86 1048998 
5-fluorocytosine – 1.1mg/ml 2 4668 1.85 1049171 
5-fluorocytosine – 1.1mg/ml 3 4669 1.85 1050947 
5-fluorocytosine – 1.1mg/ml 4 4670 1.85 1049168 
5-fluorocytosine – 1.1mg/ml 5 4671 1.85 1043723 
     
Mean    1048401 
% RSD    0.3 
 
Table 19.  (5-fluorocytosine Linearity Study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
5-fluorocytosine – 1.2mg/ml 1 4672 1.85 1121913 
5-fluorocytosine – 1.2mg/ml 2 4673 1.84 1129431 
5-fluorocytosine – 1.2mg/ml 3 4674 1.84 1120289 
5-fluorocytosine – 1.2mg/ml 4 4675 1.84 1112892 
5-fluorocytosine – 1.2mg/ml 5 4676 1.84 1114526 
     
Mean    1119810 
%RSD    0.6 
 
Table 20.  (5-fluorocytosine Linearity Study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
5-fluorocytosine – 1.3mg/ml 1 4677 1.84 1194536 
5-fluorocytosine – 1.3mg/ml 2 4678 1.84 1183564 
5-fluorocytosine – 1.3mg/ml 3 4679 1.83 1188725 
5-fluorocytosine – 1.3mg/ml 4 4680 1.83 1186047 
5-fluorocytosine – 1.3mg/ml 5 4681 1.83 1183030 
     
Mean    1187198 
%RSD    0.4 
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 Table 21. (5-fluorocytosine LOD/LOQ study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
5-fluorocytosine – 0.0005mg/ml 1 6326 1.92 683 
5-fluorocytosine – 0.0005mg/ml 2 6327 1.94 974 
5-fluorocytosine – 0.0005mg/ml 3 6328 1.92 1170 
     
Mean    943 
%RSD    26.0 
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 Table 22. (5-fluorocytosine LOD/LOQ study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
5-fluorocytosine – 0.0025mg/ml 1 6294 1.92 3047 
5-fluorocytosine – 0.0025mg/ml 2 6295 1.92 2859 
5-fluorocytosine – 0.0025mg/ml 3 6296 1.92 2898 
     
Mean    2935 
%RSD    3.4 
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Table 23.  (Nystatin – check standard analysis- nystatin_check_std_070308) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
Nystatin 0.5mg/ml  1 6344 1.55 2618910 
Nystatin 0.5mg/ml  2 6345 1.54 2579197 
     
Mean    2599053 
%RSD    1.1 
 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
Nystatin 0.5mg/ml (check) 1 6347 1.53 2690856 
Nystatin 0.5mg/ml (check) 2 6348 1.53 2651320 
Nystatin 0.5mg/ml (check) 3 6349 1.53 2622331 
Nystatin 0.5mg/ml (check) 4 6350 1.53 2660241 
Nystatin 0.5mg/ml (check) 5 6351 1.53 2632332 
     
Mean    2651416 
%RSD    1.0 
 
 
Nystatin standard weight = 500.89 mg/250ml volumetric flask 
Nystatin check standard weight = 100.18mg/50ml volumetric flask 
Standard Agreement = 98.0% 
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Table 24. (Nystatin Linearity Study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
Nystatin – 0.00025mg/ml 1 5181 1.64 13087 
Nystatin – 0.00025mg/ml 2 5182 1.65 13160 
Nystatin – 0.00025mg/ml  3 5183 1.64 13025 
Nystatin – 0.00025mg/ml 4 5184 1.64 13080 
Nystatin – 0.00025mg/ml 5 5185 1.64 13003 
     
Mean    13071 
% RSD    0.5 
 
 
 
Table 25. (Nystatin Linearity Study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
Nystatin – 0.1mg/ml 1 5186 1.62 940542 
Nystatin – 0.1mg/ml 2 5187 1.63 943536 
Nystatin – 0.1mg/ml 3 5188 1.62 931127 
Nystatin – 0.1mg/ml 4 5189 1.62 942290 
Nystatin – 0.1mg/ml 5 5190 1.61 932920 
     
Mean    938083 
% RSD    0.6 
 
 
Table 26. (Nystatin Linearity Study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
Nystatin – 0.3mg/ml 1 5191 1.64 1564255 
Nystatin – 0.3mg/ml 2 5192 1.65 1573456 
Nystatin – 0.3mg/ml 3 5193 1.65 1590276 
Nystatin – 0.3mg/ml 4 5194 1.65 1606906 
Nystatin – 0.3mg/ml 5 5195 1.65 1607174 
     
Mean    1588414 
%RSD    1.2 
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Table 27. (Nystatin Linearity Study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
Nystatin – 0.5mg/ml 1 5196 1.73 2067477 
Nystatin – 0.5mg/ml 2 5197 1.73 2128022 
Nystatin – 0.5mg/ml 3 5198 1.74 2091569 
Nystatin – 0.5mg/ml 4 5199 1.74 2097015 
Nystatin – 0.5mg/ml 5 5200 1.75 2100001 
     
Mean    2096817 
% RSD    1.0 
 
 
Table 28. (Nystatin Linearity Study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
Nystatin – 0.7mg/ml 1 5201 1.74 2429941 
Nystatin – 0.7mg/ml 2 5202 1.74 2342039 
Nystatin – 0.7mg/ml 3 5203 1.74 2358212 
Nystatin – 0.7mg/ml 4 5204 1.73 2357520 
Nystatin – 0.7mg/ml 5 5205 1.73 2409336 
     
Mean    2379409 
% RSD    1.6 
 
 
Table 29. (Nystatin Linearity Study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
Nystatin – 0.9mg/ml 1 5206 1.73 2555334 
Nystatin – 0.9mg/ml 2 5207 1.73 2556081 
Nystatin – 0.9mg/ml 3 5208 1.72 2460006 
Nystatin – 0.9mg/ml 4 5209 1.73 2490099 
Nystatin – 0.9mg/ml 5 5210 1.73 2463426 
     
Mean    2504989 
%RSD    1.9 
 
Table 30. (Nystatin Linearity Study) 
Sample Name Injection 
number 
Result 
ID 
Retention 
Time 
Area 
Nystatin – 1.1mg/ml 1 5211 1.77 2993223 
Nystatin – 1.1mg/ml 2 5212 1.77 2869904 
Nystatin – 1.1mg/ml 3 5213 1.77 2904944 
Nystatin – 1.1mg/ml 4 5214 1.77 2938168 
Nystatin – 1.1mg/ml 5 5215 1.76 2840529 
     
Mean    2909354 
%RSD     
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CONCLUSION 
 
The results of this study further support the validity of capillary electrophoresis as a 
potential alternative to HPLC when applicable.    One of the greatest challenges for 
this analytical tool is injection precision.    In comparison to HPLC, for method 
development an internal standard is commonly employed.  In this study, we show 
that with careful attention to pre-injection capillary equilibration, column 
regeneration, and ratio of organic to solvent, respectable precision results 
comparable to HPLC are obtained. The sometimes-necessary use of organic as a 
solvent can potentially have adverse effects of reproducibility. The effect of the 
organic on the electroosmotic flow can be unpredictable and only be understood after 
experimentation with a particular organic and buffer system.  In this study, both 
miconazole and nystatin were dissolved in methanol and dimethlyformamide 
respectively.  As previously discussed, initially miconazole was prepared into a 50% 
organic solution for analysis.  The %RSD values obtained from this condition were 
around 7%.  For the final studies, miconazole was prepared with 25% organic, which 
produced %RSD results of less than 2% for all seven concentrations. 
The findings were different for nystatin, due to this compounds lack of solubility in 
water. The low linearity R2 results of 0.88 illustrated solubility problems with the final 
solutions at 75% aqueous solvent level.      
Compounds that pose similar solubility challenges as Nystatin can provide more of a 
challenge for method development.   
Since 5-fluorocytosine is soluble in water, capillary electrophoresis analysis is a good 
choice of an analytical tool.  For this method, the run buffer and compound solvent 
were the same.  Linearity and precision, LOQ, and LOD results were all very 
comparable to that of HPLC. 
Miconazole and 5-fluorocytosine have shown that this technology can prove to be an 
alternative to HPLC.  Although, in fairness to HPLC, an HPLC analysis can be very 
rugged with continuous use, with relative less care to variables that may cause 
issues for capillary electrophoresis during routine operation.  
In conclusion, in the pursuit of adhering to stringent validation criteria that are 
utilized for HPLC, careful attention needs to be considered with solvent ratios, loss of 
buffer effectiveness, pre-injection capillary conditioning, and capillary regeneration.  
In addition, during routine analysis attention is needed to ensure source and 
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destination run buffer levels are comparable.  If the necessary care is taken during 
method development and instrument set-up during analysis, for some compounds 
capillary electrophoresis provides another choice of analytical tool that offers many 
advantages over HPLC. 
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